Literature DB >> 8489547

Treatment of refractory, systemic lupus erythematosus-associated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide.

B A Roach1, G J Hutchinson.   

Abstract

We describe a patient with systemic lupus erythematosus and severe, treatment-resistant thrombocytopenia. Prolonged treatment with high-dose steroids eventually led to reversal of the thrombocytopenia, but the dosage could not be tapered without relapse. Low-dose intravenous bolus cyclophosphamide was given, producing a response within 1 week. The steroid dosage was tapered, without relapse. Other than reversible alopecia, no toxicity was seen. The use of this treatment should be considered in patients in whom more conventional therapies are not effective or cannot be tolerated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8489547     DOI: 10.1002/art.1780360516

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  4 in total

1.  Steroid-resistant autoimmune thrombocytopenia in systemic lupus erythematosus treated with rituximab.

Authors:  Vasudha V Sardesai; Vidyadhar R Sardesai; Trupti D Agarwal
Journal:  Indian J Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.494

Review 2.  Haematological manifestations of lupus.

Authors:  Anum Fayyaz; Ann Igoe; Biji T Kurien; Debashish Danda; Judith A James; Haraldine A Stafford; R Hal Scofield
Journal:  Lupus Sci Med       Date:  2015-03-03

3.  Two cases of refractory thrombocytopenia in systemic lupus erythematosus that responded to intravenous low-dose cyclophosphamide.

Authors:  Hee-Jin Park; Mi-Il Kang; Yoon Kang; Soo-Jin Chung; Sang-Won Lee; Yong-Beom Park; Soo-Kon Lee
Journal:  J Korean Med Sci       Date:  2013-03-04       Impact factor: 2.153

4.  Thrombocytopenia in Systemic Lupus Erythematosus: Clinical Manifestations, Treatment, and Prognosis in 230 Patients.

Authors:  Jin-Hee Jung; Moon-Seung Soh; Young-Hwan Ahn; Yoo-Jin Um; Ju-Yang Jung; Chang-Hee Suh; Hyoun-Ah Kim
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.